EASL Extraordinary General Assembly – Wednesday, 27 November 2024, 17:00-19:00 CET
At the upcoming Extraordinary General Assembly, the EASL Governing Board will present an update on the 2024 activities and a forecast of the 2024 budget. Furthermore, the Governing Board will present the…
Call for nominations and applications for EASL Awards 2025
We are excited to announce the launch of the call for nominations and applications for three prestigious awards: the EASL Community Award 2025, the EASL Emerging Leader Award 2025, and the EASL…
Interview with Sarina Shabso, 2024 Daniel Alagille Awardee
The recipient of the 2024 Daniel Alagille Award, Sarina Shabso, discusses her inspiring journey into the field of hepatology. Shabso's path, from her early focus on skin regeneration to her groundbreaking research…
Interview with Scott Waddell, 2023 Daniel Alagille Awardee
In an insightful conversation with EASL, Scott Waddell, the recipient of the 2023 Daniel Alagille Award, shares his journey into the field of hepatology. From his initial focus on cholangiocarcinoma to his…
Join the EASL Educational Committee!
The EASL Educational Committee provides scientific expertise and support to the EASL Governing Board and EASL office, in the development and monitoring of a high-quality portfolio of educational offerings in support of…
European Medicines Association (EMA) statement on Obeticholic acid for the treatment of primary biliary cholangitis (PBC) European Association for the Study of the Liver (EASL) perspective
The EMA human medicines committee (CHMP) has recently issued a statement on Obeticholic acid for the treatment of Primary Biliary Cholangitis (PBC). The CHMP recommended to the European Commission that the market…
First Patient Enrolled in Phase II Clinical Trial of DECISION’s COMBAT Trial
• First patient enrolled at Hôpital Beaujon, Clichy, France • The COMBAT Trial is a multicenter, randomized, open-label, Phase II clinical trial in patients with decompensated cirrhosis Barcelona, Spain, 9th July 2024…